VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer

Hamilton, Erika P, Ma, Cynthia, De Laurentiis, Michelino · Future Oncology · 2024